Published 2 days ago • loading... • Updated 2 days ago

Pharma’s $500B patent problem will come in waves — not as a cliff

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

1 Articles

PharmaVOICE

Center

Pharma’s $500B patent problem will come in waves — not as a cliff

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated2 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PharmaVOICE broke the news 2 days ago on Thursday, October 8, 2026.

Sources are mostly out of (0)

Pharma’s $500B patent problem will come in waves — not as a cliff

1 Articles

1 Articles

Pharma’s $500B patent problem will come in waves — not as a cliff

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO

The Ranking of the Best Companies Where to Work: in the Top 100 Chiesi and Bending Spoons

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Pharmaceutical Order Says OE2027 "Belows" the Sector's Potential

Halozyme wins court order to block Merck’s injected Keytruda in select European markets

Similar News Topics

Similar News Topics

More stories like this

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO

The Ranking of the Best Companies Where to Work: in the Top 100 Chiesi and Bending Spoons

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Pharmaceutical Order Says OE2027 "Belows" the Sector's Potential

Halozyme wins court order to block Merck’s injected Keytruda in select European markets

Pharma’s $500B patent problem will come in waves — not as a cliff

1 Articles

1 Articles

Pharma’s $500B patent problem will come in waves — not as a cliff

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO

The Ranking of the Best Companies Where to Work: in the Top 100 Chiesi and Bending Spoons

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Pharmaceutical Order Says OE2027 "Belows" the Sector's Potential

Halozyme wins court order to block Merck’s injected Keytruda in select European markets

Similar News Topics

Similar News Topics

More stories like this

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO

The Ranking of the Best Companies Where to Work: in the Top 100 Chiesi and Bending Spoons

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Pharmaceutical Order Says OE2027 "Belows" the Sector's Potential

Halozyme wins court order to block Merck’s injected Keytruda in select European markets

Bias Distribution

Factuality